ATTR-CM is an underdiagnosed, progressive, and infiltrative disease that can often be overlooked as a cause of heart failure.1,3 Prognosis worsens rapidly with continued amyloid deposition, subsequent advancing organ dysfunction, and significant reduction in quality of life.1,2
Once diagnosed, untreated patients with ATTR-CM have a median survival of ~2 to 3.5 years.2
TTR is a transport protein for a thyroid hormone (thyroxine [T4]) and is a retinol-binding protein.5 The mechanism of the disease (MOD) underscores the important function of TTR protein and the consequence of destabilisation for your patients.
98% of currently diagnosed cardiac amyloidosis cases result from fibrils composed of ATTR or monoclonal immunoglobulin light chains (immunoglobulin light chain amyloidosis, or AL).6
ATTR-CM is one of the most common types of cardiac amyloidosis2,7,8
Patients with ATTR-CM can present with additional manifestations such as atrial fibrillation, bilateral carpal tunnel syndrome, or peripheral neuropathy.2,3,10,12,13
A well-coordinated health care team with expertise in different specialties and diagnostic modalities can offer patients comprehensive care when diagnosing ATTR-CM.6,11
Meet Dr. Detective, a cardiologist who specialises in diagnosing tough cases. Watch as he learns more about ATTR-CM.
Raising suspicion of ATTR-CM
Gain a deeper understanding of echocardiography and cardiac magnetic resonance (CMR).
Review the evidence and consensus recommendations for diagnosis.
Adverse events should be reported. Report an adverse event to your national reporting system (HPRA Pharmacovigilance)
Adverse events should also be reported to Pfizer Medical Information on 1800 633 363
Please sign in or register to gain access to information relating to Pfizer medicines and vaccines, medical conditions, patient materials and services.
This site is intended only for healthcare professionals resident in the Republic of Ireland. If you are a member of the public wishing to access information on a specific medicine, please visit https://www.medicines.ie
This website is brought to you by Pfizer Healthcare Ireland, 9 Riverwalk, National Digital Park, Citywest Business Campus, Dublin 24, Ireland. Registered in the Republic of Ireland No. 127002.
Copyright © 2023 Pfizer Limited. All rights reserved.
The information contained on this site is reserved exclusively for healthcare professionals resident in the Republic of Ireland.
I confirm that I am a healthcare professional resident in the Republic of Ireland.*
If you select 'No', you will be redirected to Pfizer.ie, where you will be able to access information on Pfizer Healthcare Ireland.
PP-UNP-IRL-0176. January 2023